Ignite Creation Date:
2025-12-24 @ 9:54 PM
Ignite Modification Date:
2025-12-25 @ 7:33 PM
Study NCT ID:
NCT04569032
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-12
First Post:
2020-09-23
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-11-12
Start Date Type:
ACTUAL
Primary Completion Date:
2024-05-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-09-23
First Submit QC Date:
None
Study First Post Date:
2020-09-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-04-28
Results First Submit QC Date:
None
Results First Post Date:
2025-05-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-11
Last Update Post Date:
2025-09-12
Last Update Post Date Type:
ESTIMATED